XML 70 R56.htm IDEA: XBRL DOCUMENT v3.21.2
Geneos Therapeutics, Inc. - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended 7 Months Ended 9 Months Ended
Jun. 01, 2020
Nov. 30, 2020
Feb. 28, 2019
Sep. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Dec. 31, 2020
Sep. 30, 2021
Sep. 30, 2020
Jun. 30, 2021
Feb. 28, 2021
Jun. 30, 2020
Mar. 31, 2020
Jan. 31, 2020
Noncontrolling Interest [Line Items]                            
Gain on deconsolidation of investment       $ 0   $ 0   $ 0 $ 4,121,075          
Share of net loss in Geneos       0   $ 1,759,674   434,387 $ 2,661,431          
Investment in equity method investments       $ 0     $ 434,387 $ 0            
Series A One Preferred Stock                            
Noncontrolling Interest [Line Items]                            
Investment in equity method investments $ 1,399,999                          
Geneos Therapeutics, Inc.                            
Noncontrolling Interest [Line Items]                            
Noncontrolling interest, ownership percentage by parent   36.00% 61.00%               35.00%   52.00%  
Ownership percentage       47.00%       47.00%       47.00%    
Geneos Therapeutics, Inc.                            
Noncontrolling Interest [Line Items]                            
Payments to acquire additional interest in subsidiaries   $ 1,400,000 $ 1,200,000                      
Stock purchase agreement, commitment of additional investment                       $ 800,000   $ 800,000
Gain on deconsolidation of investment 4,121,075                          
Deconsolidation gain, remeasurement of retained noncontrolling investment to fair value 2,400,000                          
Loss from equity method investment, recorded and allocated to investment         $ (1,500,000)   (4,600,000)              
Share of net loss in Geneos         434,387   4,584,610              
Investment in equity method investments 3,618,998     $ 0 $ 0     $ 0            
Geneos Therapeutics, Inc. | Common stock                            
Noncontrolling Interest [Line Items]                            
Investment in equity method investments 819,000                 $ 0        
Geneos Therapeutics, Inc. | Preferred stock                            
Noncontrolling Interest [Line Items]                            
Share of net loss in Geneos             4,200,000              
Investment in equity method investments $ 2,799,998                 $ 0        
Geneos Therapeutics, Inc. | Series A One Preferred Stock                            
Noncontrolling Interest [Line Items]                            
Share of net loss in Geneos             $ 819,000